Cargando…

2380. Healthcare Resource Utilization for High-Risk Patients Treated With Dalbavancin in Physician Office Infusion Centers (POICs)

BACKGROUND: Medicare beneficiaries and patients (patients) ≥65 years comprise the highest risk for utilization of healthcare resources including emergency department (ED) visits and hospitalizations (hosp). Dalbavancin (DAL) is a long-acting lipoglycopeptide approved for treatment of bacterial skin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luu, Quyen, Statner, Barry, Dretler, Robin H, Baker, H Barry, Metzger, Brian S, Hardin, Thomas C, Schroeder, Claudia P, Anglen, Lucinda J Van
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255471/ http://dx.doi.org/10.1093/ofid/ofy210.2033

Ejemplares similares

597. The Impact of COVID-19 on Outpatient Intravenous Antimicrobial Therapy (OPAT) in Physician Office Infusion Centers (POICs)
por: Martin, Clifford P, et al.
Publicado: (2021)

2367. Infection Incidence and Utilization of Antimicrobials in Physician Office Infusion Centers (POICs)
por: Van Anglen, Lucinda J, et al.
Publicado: (2018)

2494. Real-World Use of Ibalizumab in Physician Office Infusion Centers (POICs)
por: Prokesch, Richard C, et al.
Publicado: (2019)

763 Low Hospital Admission Rates Following Physician Office Infusion Center (POIC)-Based Outpatient Treatment with Intravenous Antibiotics (IVABs)
por: Alvarado, Fernando S., et al.
Publicado: (2014)

1016. Real-World Use of Omadacycline in Physician Office Infusion Centers (POICs)
por: Van Anglen, Lucinda J, et al.
Publicado: (2022)

750. Serious Bacterial Infections: Successful Outpatient Management by Infectious Disease Physicians in Office Infusion Centers
por: Adams, John S, et al.
Publicado: (2019)

313. Outpatient Treatment and Recurrence of Prosthetic Joint Infection (PJI) in Infectious Disease (ID) Physician Office Infusion Centers (POICs): A 2-Year Retrospective Multicenter Analysis
por: Metzger, Brian S, et al.
Publicado: (2018)

755 Comparison of Outpatient Antimicrobial Therapy (OPAT) in a Physician Office Infusion Center (POIC) vs Traditional Home Health Care (HHC)
por: Prokesch, Richard C., et al.
Publicado: (2014)

1625. Real-World Outpatient Utilization of Ceftolozane/Tazobactam in Physician Office Infusion Centers (OICs)
por: Van Anglen, Lucinda J, et al.
Publicado: (2020)

598. A 3-Year Evaluation of Antibiotic Resistance Patterns in Gram-Negative Genitourinary Tract Infections Treated in Outpatient Infusion Centers (POICs)
por: Hengel, Richard L, et al.
Publicado: (2021)

2081. Low 30-Day Hospital Readmission Rates in Medicare Patients Receiving Outpatient Parenteral Antimicrobial Therapy (OPAT) in Physician Office Infusion Centers
por: Luu, Quyen, et al.
Publicado: (2019)

1327. Vancomycin Dosing by AUC(24)/MIC in Comparison to Traditional Trough Dosing in Office Infusion Centers (OICs)
por: Luu, Quyen, et al.
Publicado: (2020)

Successful Establishment of an Antimicrobial Stewardship Program (ASP) for Outpatient Parenteral Antimicrobial Therapy (OPAT)
por: Nathan, Ramesh V, et al.
Publicado: (2017)

2380. Menstrual changes after COVID vaccine in the Dominican Republic
por: Roque, Yori A, et al.
Publicado: (2023)

Safety and Effectiveness of Outpatient Parenteral Antimicrobial Therapy (OPAT) in the Aged Population
por: Van Anglen, Lucinda J, et al.
Publicado: (2017)

614. Long-Acting Lipoglycopeptides for the Treatment of Bone and Joint Infections and Bacteremia in Infectious Disease Outpatient Infusion Clinics
por: Metzger, Brian S, et al.
Publicado: (2020)

1854. Effective Antimicrobial Stewardship for Outpatient Parenteral Antimicrobial Therapy (OPAT): Nationwide Experience in Infectious Disease Physician Infusion Centers
por: Nathan, Ramesh V, et al.
Publicado: (2018)

Dalbavancin
por: Barberán, José, et al.
Publicado: (2021)

Mycobacterium marinum MMAR_2380, a predicted transmembrane acyltransferase, is essential for the presence of the mannose cap on lipoarabinomannan
por: Driessen, Nicole N., et al.
Publicado: (2010)

2380. Fecal Collinsella Abundance is Negatively Associated with Toxin A/B Production in Cancer Patients with Clostridioides difficile
por: A. Francisco, Denise Marie, et al.
Publicado: (2019)

501. Evaluation of Bezlotoxumab in Prevention of Recurrent C. difficile Infection: A Multicenter Single-Arm Study in Outpatient Infusion Centers
por: Hengel, Richard L, et al.
Publicado: (2018)

Dalbavancin: a novel antimicrobial
por: Chen, A Y, et al.
Publicado: (2007)

A Real-world Multicenter Outpatient Experience of Ceftolozane/Tazobactam
por: Van Anglen, Lucinda J, et al.
Publicado: (2023)

PB2380: DEVELOPING GENOMIC TESTS THAT GUIDE LARGE B-CELL LYMPHOMA DIAGNOSIS AND TREATMENT: LYMPH2CX AND LYMPH3CX ASSAYS
por: Robetorye, Ryan S., et al.
Publicado: (2023)

Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram Infusion
por: Rappo, Urania, et al.
Publicado: (2019)

2382. Recurrent Clostridioides difficile Infection (CDI) Worsens Anxiety-Related Patient-Reported Quality of Life
por: Garey, Kevin W, et al.
Publicado: (2019)

267 Dalbavancin for the treatment of Streptococcal Skin Infections
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

Successful Treatment of Diabetic Foot Osteomyelitis with Dalbavancin
por: Loupa, Chariclia V., et al.
Publicado: (2020)

Dalbavancin: novel candidate for COVID-19 treatment
por: Hoffmann, Markus, et al.
Publicado: (2021)

Evaluating the Use of Dalbavancin for Off-Label Indications
por: Taylor, Katherine, et al.
Publicado: (2022)

Global trends of dalbavancin: A bibliometric analysis
por: Monteagudo‐Martínez, Nuria, et al.
Publicado: (2022)

The Effect of Dalbavancin in Moderate to Severe Hidradenitis Suppurativa
por: Molinelli, Elisa, et al.
Publicado: (2022)

Dalbavancin for Staphylococcus aureus Bacteremia: Are We There Yet?
por: Mahatanan, Rattanaporn, et al.
Publicado: (2023)

2902. Dalbavancin Use in Bone and Joint Infections
por: Sanikommu, Srivani, et al.
Publicado: (2023)

2764. Experience with dalbavancin in a pediatric hospital
por: Leon, Maria Deza, et al.
Publicado: (2023)

610. Low Rates of Acute Kidney Injury (AKI) in Outpatient Vancomycin Managed by Pharmacists using Precision Dosing Software
por: Schroeder, Claudia P, et al.
Publicado: (2022)

589. Use of Dalbavancin in Facilitating Discharge of High Risk Patients in Low Resource Settings
por: Milgrom, Alexander
Publicado: (2020)

787. Evaluation of Clostridioides difficile Environmental Contamination Surrounding C. difficile Patients vs. non-C. difficile Patients in Outpatient Infusion Centers
por: Garey, Kevin W, et al.
Publicado: (2020)

Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis
por: Carrothers, Timothy J., et al.
Publicado: (2019)

1268. Dalbavancin for the Treatment of Infections due to Staphylococcus aureus
por: Streifel, Amber C, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fc8l2qi92emced4do3qun7obpk